The target audience is pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with gram-negative infections as well as pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy.
The goal of this program is to improve the knowledge and competence of learners about applying the latest practice guidelines and data for selection of antibiotic regimens for patients with complex infections with MDROs and XDROs.
Upon completion of this activity, participants should be able to:
Differentiate clinically relevant multidrug and extensively drug–resistant gram-negative organisms (MDROs, XDROs) including epidemiology, mechanisms of antimicrobial resistance, and virulence factors
Compare available antimicrobial agents for difficult-to-treat gram-negative pathogens, including data on efficacy, adverse events, pharmacokinetics/pharmacodynamics, and antimicrobial spectrum coverage
Integrate clinical guidelines, individual patient factors, and laboratory data into the selection of optimal treatment regimens for patients with antimicrobial-resistant gram-negative infections
Develop strategies to minimize time to effective therapy, incorporating rapid diagnostics and antimicrobial stewardship principles
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learning with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of ineligible company.
The faculty reported the following relevant financial relationships to products or devices they have with ineligible companies related to the content of this educational activity.
Elias B. Chahine, PharmD, FCCP, FASCP, FFSHP, BCPS, BCIDP: consultant/advisor/speaker: Gilead, Seqirus, Shinogi, Theratechnologies.
Jaclyn Cusumano, PharmD, BCIDP: consultant/advisor/speaker: Shionogi.
The planners and content peer reviewers from ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP) do not have any relevant financial relationships to disclose.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities
This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-003-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.